Drug

Multikinase Inhibitor AEE788

CI-DRUG-00000389Explore in graph →NCIt C48369 CIViC

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	0	0	0	3	0	—	—	2003-07
Malignant Central Nervous System Neoplasm	Phase2	Phase 2	0	0	0	1	0	—	—	2004-01

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 3 hours agoSource updated unknown

Curated evidence

Clinical evidence (7)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–7 of 7 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR T790M2
Gefitinib + Multikinase Inhibitor AEE788

Clinical trials

Trials with this intervention (3)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–3 of 3 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00116376	Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)	completed	Phase 1 / Phase 2	64	Novartis PharmaceuticalsINDUSTRY	1	Nov 10, 2015	clinicaltrials
NCT00107237	AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme	completed	Phase 1 / Phase 2

EGFR D761N1
Multikinase Inhibitor AEE788	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID5821 EGFR D716N was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic

EGFR D761N1

Multikinase Inhibitor AEE788

Malignant NeoplasmALIAS

Predictive

Supports Sensitivity Response

submitted

EID5821

EGFR D716N was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

civic

EGFR G810S1
Multikinase Inhibitor AEE788	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID5825 EGFR G810S was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic

EGFR G810S1

Multikinase Inhibitor AEE788

Malignant NeoplasmALIAS

Predictive

Supports Sensitivity Response

submitted

EID5825

EGFR G810S was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

civic

EGFR L858R1
Erlotinib + Gefitinib + Multikinase Inhibitor AEE788Substitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID3811 EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic

EGFR L858R1

Erlotinib + Gefitinib + Multikinase Inhibitor AEE788Substitutes

Malignant NeoplasmALIAS

Predictive

Supports Sensitivity Response

accepted

EID3811

EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

civic

EGFR L861Q1
Erlotinib + Gefitinib + Multikinase Inhibitor AEE788Substitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	2	submitted	EID5826 EGFR L861Q was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic

EGFR L861Q1

Erlotinib + Gefitinib + Multikinase Inhibitor AEE788Substitutes

Malignant NeoplasmALIAS

Predictive

Does Not Support Sensitivity Response

submitted

EID5826

EGFR L861Q was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

civic

EGFR S784F1
Multikinase Inhibitor AEE788	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID5823 EGFR S784F was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC) PMID 19147750 · Kancha et al., 2009 · Open in CIViC	civic

EGFR S784F1

Multikinase Inhibitor AEE788

Malignant NeoplasmALIAS

Predictive

Supports Sensitivity Response

submitted

EID5823

EGFR S784F was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors G… (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

civic